Next-Generation AVAC Fellows: A call for 2022 applications

Email Updates

You are here

Home»Media

AVAC in the News

  • Most COVID-19 Vaccines Won’t Affect HIV Risk: Here’s What the Science Tells Us

    We can now see a light at the end of the COVID-19 tunnel, thanks to a growing amount of positive news on vaccines in development. There are many COVID-19 vaccines in the pipeline, and most—including the three that are currently the farthest along in development (one by Moderna, one by PFizer/BioNTech, and one by AstraZeneca/Oxford)—do not present any concern when it comes to potential HIV risk.

    December 2, 2020
    General
    The Body

  • Tortoise and the Hare: Why a COVID Vaccine Is Outrunning Its HIV Counterpart

    Four COVID jabs’ efficacy results have been released within less than a year after the trials had started. But this is far from the norm. Researchers have been working on HIV vaccines for over three decades — and we still don’t have one. Here’s why.

    December 1, 2020
    HIV Vaccine
    Bhekisisa

  • ‘Your Life Is Altered, but It’s Not the End’: Life With HIV, Stigma and Discrimination

    The dark days of the HIV pandemic are over, but patients still face social stigma and emotional distress that can push them to stop treatment or even into a deep depression. Hear it first-hand from people who’ve experienced it.

    November 30, 2020
    General
    Bhekisisa

  • Multi-Stakeholder Consensus on a Target Product Profile for an HIV Cure

    Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy.

    November 30, 2020
    Cure
    Lancet HIV

  • The Case for an HIV Cure and How to Get There

    We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.

    November 30, 2020
    Cure
    Lancet HIV

  • The Long Darkness Before Dawn

    Each week, good news about vaccines or antibody treatments surfaces, offering hope that an end to the pandemic is at hand. And yet this holiday season presents a grim reckoning. The United States has reached an appalling milestone: more than one million new coronavirus cases every week. Hospitals in some states are full to bursting. The number of deaths is rising and seems on track to easily surpass the 2,200-a-day average in the spring, when the pandemic was concentrated in the New York metropolitan area.

    November 30, 2020
    General
    New York Times

  • U=U: We Should Put People Living With HIV at the Centre of HIV Prevention Efforts

    The message is simple to understand. An undetectable viral load in people living with HIV equals an untransmissible virus. The success of this concept, however, depends on strict adherence to antiretroviral therapy (ART).

    November 24, 2020
    Treatment
    Spotlight

  • Opinion: Why Exciting Results From Vaccine Research Are Just the Beginning of Efforts to End COVID-19

    The news last week and again this week that at least two highly effective vaccines may be on the horizon is a welcome respite from the devastating impact of COVID-19 on global health. In under a year, SARS-CoV-2 has already caused more than 56 million infections and 1.3 million deaths.

    November 19, 2020
    General
    Devex

  • Six Injections a Year Could Stop New HIV Infections

    Six shots a year of an antiretroviral (ARV) drug can protect women from contracting HIV, new research shows. Activists say although the jab won’t be available immediately, countries need to start doing the planning—and the math—to introduce the bimonthly injection now.

    November 16, 2020
    PrEP
    Mail & Guardian

  • Study Finds Long-Acting Shot Helps Women Avoid HIV Infection

    Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help keep women from catching HIV from an infected sex partner.

    November 9, 2020
    PrEP
    Washington Post

Pages